COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,198 Articles (22,713 medRxiv, 8,485 bioRxiv)

Most recent first Previous |  Page 173: Articles 1721-1730  | Next

Genome-wide association study of COVID-19 Breakthrough Infections and genetic overlap with other diseases: A study of the UK Biobank
FENG, Y., Wong, K. C. Y., TSUI, W. K., ZHANG, R., XIANG, Y., So, H.-C.
10.1101/2024.08.11.24311845 — Posted: 2024-08-12
Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic
Whittaker, C., Barnsley, G., Olivera Mesa, D., Laydon, D. J., Tan, C. W., Zhu, F., Johnson, R., Doohan, P., Nedjati-Gilani, G., Winskill, P., Hogan, A., Deol, A., Mukandavire, C., Hauck, K., Lye, D. C. B., Wang, L.-F., Watson, O. J., Ghani, A.
10.1101/2024.08.12.24311730 — Posted: 2024-08-12
Health-related quality of life in Long COVID: Mapping the condition-specific C19-YRSm measure onto the EQ-5D-5L
Smith, A. B., Greenwood, D. C., Williams, P., Kwon, J., Petrou, S., Horton, M., Osbourne, T., Milne, R., Sivan, M.
10.1101/2024.08.11.24311809 — Posted: 2024-08-11
Use of Biochemical Biomarkers to Evaluate the Role of Oxidative Stress in the Progression of COVID-19 Severity
Marcano, L. A., Lugo, R. S.
10.1101/2024.08.11.24311803 — Posted: 2024-08-11
The adaptive immune responses to SARS-CoV-2 as a recall response susceptible to immune imprinting
Alvarez-Sierra, D., Martinez-Gallo, M., Sanchez-Montalva, A., Fernandez-Sanmartin, M. A., Colobran, R., Espinosa-Pereiro, J., Poyatos-Canton, E., Sanchez-Pla, A., Zurera-Egea, C., Violan, C., Parra, R., Halzayat, H., Vivancos, A., Morandeira-Rego, F., Urban-Vargas, B., Martinez-Caceres, E., Hernandez-Gonzalez, M., Bas-Minguet, J., Teniente-Serra, A., Katsikis, P., Pujol Borrell, R.
10.1101/2024.08.11.24311358 — Posted: 2024-08-11
A pan-variant miniprotein inhibitor protects against SARS-CoV-2 variants
Lee, J., Case, J. B., Ravichandran, R., Asarnow, D., Tortorici, M. A., Brown, J. T., Sanapala, S., Carter, L., Baker, D., Diamond, M. S., Veesler, D.
10.1101/2024.08.08.606885 — Posted: 2024-08-10
Eosinophils protect against SARS-CoV-2 following a vaccine breakthrough infection
Moore, K. M., Foster, S. L., Elrod, E. J., Floyd, K. A., Williams, M. E., Kar, M., Vander Velden, J., Ellis, M., Malik, A., Wali, B., Lapp, S., Metz, A., Bosinger, S. E., Seder, R. A., Amara, R. R., Menachery, V. D., Kohlmeier, J. E., Grakoui, A., Suthar, M. S.
10.1101/2024.08.08.607190 — Posted: 2024-08-10
Enhancing SARS-CoV-2 Lineage surveillance through the integration of a simple and direct qPCR-based protocol adaptation with established machine learning algorithms
Aksenen, C. F., Ferreira, D. M. A., Jeronimo, P. M. C., Costa, T. d. O., de Souza, T. C., Lino, B. M. N. S., de Farias, A. A., Miyajima, F.
10.1101/2024.08.09.24310239 — Posted: 2024-08-10
Impacts on labour force and healthcare services related to mental-health issues following an acute SARS-CoV-2 infection: rapid review
Bialy, L., Pillay, J., Saba, S., Guitard, S., Rahman, S., Tan, M., Hartling, L.
10.1101/2024.08.09.24311746 — Posted: 2024-08-10
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
Suryawanshi, R. K., Jaishankar, P., Correy, G. J., Rachman, M. M., O'Leary, P. C., Taha, T. Y., Zapatero-Belinchon, F. J., McCavitt-Malvido, M., Doruk, Y. U., Stevens, M. G. V., Diolati, M. E., Jogalekar, M. P., Richards, A. L., Montano, M., Rosecrans, J., Matthay, M., Togo, T., Gonciarz, R. L., Gopalkrishnan, S., Neitz, R. J., Krogan, N. J., Swaney, D. L., Shoichet, B. K., Ott, M., Renslo, A. R., Ashworth, A., Fraser, J. S.
10.1101/2024.08.08.606661 — Posted: 2024-08-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).